Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Trial details
- Registry ID
- NCT05201404
- Drugs studied
- Namodenoson
TrialRedline tracks 6 clinical trials sponsored by Can-Fite BioPharma: 2 Phase 3, 4 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisNCT05201404 | Namodenoson | Recruiting | 2026-02Estimated |
| A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyNCT06643260 | piclidenoson | Not yet recruiting | 2027-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Namodenoson Treatment of Advanced Pancreatic CancerNCT06387342 | Namodenoson 25mg | Recruiting | 2026-07-15Estimated |
| An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe SyndromeNCT07410455 | Piclidenoson | Not yet recruiting | 2027-08-31Estimated |
| Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis PatientsNCT00280917 | CF101 | Completed | 2007-04Actual |
| Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)NCT04697810 | Namodenoson | Unknown | 2025-04-15Estimated |
Names as written in the registry records.